TY - JOUR AU - Ghassemian, Arian AU - Park, Jane Jiyoon AU - Tsoulis, Michael W. AU - Kim, Harold PY - 2021 DA - 2021/01/06 TI - Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts JO - Allergy, Asthma & Clinical Immunology SP - 3 VL - 17 IS - 1 AB - Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on eosinophils. Both therapies reduce oral corticosteroid requirements and asthma exacerbations. However, no head-to-head studies have been published. The aim of the present study was to compare the efficacy of peripheral eosinophil reduction of mepolizumab and benralizumab. SN - 1710-1492 UR - https://doi.org/10.1186/s13223-020-00507-0 DO - 10.1186/s13223-020-00507-0 ID - Ghassemian2021 ER -